Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

The nonhuman primate as a model for type 2 diabetes.

Pound LD, Kievit P, Grove KL.

Curr Opin Endocrinol Diabetes Obes. 2014 Apr;21(2):89-94. doi: 10.1097/MED.0000000000000043. Review.

PMID:
24569549
2.

Resveratrol prevents β-cell dedifferentiation in nonhuman primates given a high-fat/high-sugar diet.

Fiori JL, Shin YK, Kim W, Krzysik-Walker SM, González-Mariscal I, Carlson OD, Sanghvi M, Moaddel R, Farhang K, Gadkaree SK, Doyle ME, Pearson KJ, Mattison JA, de Cabo R, Egan JM.

Diabetes. 2013 Oct;62(10):3500-13. doi: 10.2337/db13-0266. Epub 2013 Jul 24.

3.

Association of pancreatitis with glucagon-like peptide-1 agonist use.

Anderson SL, Trujillo JM.

Ann Pharmacother. 2010 May;44(5):904-9. doi: 10.1345/aph.1M676. Epub 2010 Apr 6. Review.

PMID:
20371755
4.

Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes.

Moffett RC, Patterson S, Irwin N, Flatt PR.

Diabetes Metab Res Rev. 2015 Mar;31(3):248-55. doi: 10.1002/dmrr.2608. Epub 2014 Nov 18.

PMID:
25256010
5.

GLP-1 agonists in type 1 diabetes.

Pettus J, Hirsch I, Edelman S.

Clin Immunol. 2013 Dec;149(3):317-23. doi: 10.1016/j.clim.2013.04.006. Epub 2013 Apr 17. Review.

PMID:
23643354
6.

Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes.

Sesti G.

Diabetes Obes Metab. 2009 Dec;11 Suppl 3:4-10. doi: 10.1111/j.1463-1326.2009.01072.x. Review.

PMID:
19878256
7.

Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.

Ha TY, Kim YS, Kim CH, Choi HS, Yang J, Park SH, Kim DH, Rhee JK.

Arch Pharm Res. 2014 May;37(5):671-8. doi: 10.1007/s12272-013-0209-0. Epub 2013 Jul 30.

PMID:
23897163
8.

Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.

Boland CL, Degeeter M, Nuzum DS, Tzefos M.

Ann Pharmacother. 2013 Apr;47(4):490-505. doi: 10.1345/aph.1R444. Epub 2013 Apr 2. Review.

PMID:
23548652
9.

Expression of CTRP3, a novel adipokine, in rats at different pathogenic stages of type 2 diabetes mellitus and the impacts of GLP-1 receptor agonist on it.

Li X, Jiang L, Yang M, Wu YW, Sun SX, Sun JZ.

J Diabetes Res. 2014;2014:398518. doi: 10.1155/2014/398518. Epub 2014 Aug 11.

10.

Exenatide and weight loss.

Bradley DP, Kulstad R, Schoeller DA.

Nutrition. 2010 Mar;26(3):243-9. doi: 10.1016/j.nut.2009.07.008. Review.

PMID:
20152707
11.

Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus.

Asche CV, Hippler SE, Eurich DT.

Pharmacoeconomics. 2014 Jan;32(1):15-27. doi: 10.1007/s40273-013-0117-7. Review.

PMID:
24357160
12.

Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.

Davies M, Speight J.

Diabetes Obes Metab. 2012 Oct;14(10):882-92. doi: 10.1111/j.1463-1326.2012.01595.x. Epub 2012 Apr 17. Review.

PMID:
22420869
13.

[Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].

Camafort-Babkowski M.

Med Clin (Barc). 2013 Aug 17;141(4):167-74. doi: 10.1016/j.medcli.2012.11.016. Epub 2013 Jan 18. Review. Spanish.

PMID:
23332622
14.

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.

Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL.

BMJ. 2012 Jan 10;344:d7771. doi: 10.1136/bmj.d7771. Review.

15.

Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.

Sullivan TJ, Miao Z, Zhao BN, Ertl LS, Wang Y, Krasinski A, Walters MJ, Powers JP, Dairaghi DJ, Baumgart T, Seitz LC, Berahovich RD, Schall TJ, Jaen JC.

Metabolism. 2013 Nov;62(11):1623-32. doi: 10.1016/j.metabol.2013.06.008. Epub 2013 Aug 15.

PMID:
23953944
16.

Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.

Tzefos M, Harris K, Brackett A.

Ann Pharmacother. 2012 Jan;46(1):68-78. doi: 10.1345/aph.1Q379. Review.

PMID:
22232377
17.

Liraglutide in the management of type 2 diabetes.

Wajcberg E, Amarah A.

Drug Des Devel Ther. 2010 Oct 22;4:279-90. doi: 10.2147/DDDT.S10180. Review.

20.

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.

Russell S.

Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22. Review.

PMID:
23263796

Supplemental Content

Support Center